Cyr61 as mediator of Src signaling in triple negative breast cancer cells

María Pilar Sánchez-Bailón, Annarica Calcabrini, Víctor Mayoral-Varo, Agnese Molinari, Kay Uwe Wagner, Jesús Pérez Losada, Sergio Ciordia, Juan Pablo Albar, Jorge Martín-Pérez

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

SFKs are involved in tumorigenesis and metastasis. Here we analyzed c-Src contribution to initial steps of metastasis by tetracycline-dependent expression of a specific shRNA-c-Src, which suppressed c-Src mRNA and protein levels in metastatic MDA-MB-231 cells. c-Src suppression did not alter cell proliferation or survival, but it significantly reduced anchorage-independent growth. Concomitantly with diminished tyrosine-phosphorylation/activation of Fak, caveolin-1, paxillin and p130CAS, c-Src depletion also inhibited cellular migration, invasion and transendothelial migration. Quantitative proteomic analyses of the secretome showed that Cyr61 levels, which were detected in the exosomal fraction, were diminished upon shRNA-c-Src expression. In contrast, Cyr61 expression was unaltered inside cells. Cyr61 partially colocalized with cis-Golgi gp74 marker and with exosomal marker CD63, but c-Src depletion did not alter their cellular distribution. In SUM159PT cells, transient c-Src suppression also reduced secreted exosomal Cyr61 levels. Furthermore, conditional expression of a c-Src dominant negative mutant (SrcDN, c-Src-K295M/Y527F) in MDA-MB-231 and in SUM159PT diminished secreted Cyr61 as well. Cyr61 transient suppression in MDA-MB-231 inhibited invasion and transendothelial migration. Finally, in both MDA-MB-231 and SUM159PT, a neutralizing Cyr61 antibody restrained migration. Collectively, these results suggest that c-Src regulates secreted proteins, including the exosomal Cyr61, which are involved in modulating the metastatic potential of triple negative breast cancer cells.

Original languageEnglish (US)
Pages (from-to)13520-13538
Number of pages19
JournalOncotarget
Volume6
Issue number15
DOIs
StatePublished - Jan 1 2015

Fingerprint

Triple Negative Breast Neoplasms
Transendothelial and Transepithelial Migration
Small Interfering RNA
Paxillin
Neoplasm Metastasis
Caveolin 1
Tetracycline
Neutralizing Antibodies
Proteomics
Tyrosine
Cell Survival
Carcinogenesis
Proteins
Phosphorylation
Cell Proliferation
Messenger RNA
Growth

Keywords

  • C-Src
  • Cyr61
  • Invasion
  • Migration
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Sánchez-Bailón, M. P., Calcabrini, A., Mayoral-Varo, V., Molinari, A., Wagner, K. U., Losada, J. P., ... Martín-Pérez, J. (2015). Cyr61 as mediator of Src signaling in triple negative breast cancer cells. Oncotarget, 6(15), 13520-13538. https://doi.org/10.18632/oncotarget.3760

Cyr61 as mediator of Src signaling in triple negative breast cancer cells. / Sánchez-Bailón, María Pilar; Calcabrini, Annarica; Mayoral-Varo, Víctor; Molinari, Agnese; Wagner, Kay Uwe; Losada, Jesús Pérez; Ciordia, Sergio; Albar, Juan Pablo; Martín-Pérez, Jorge.

In: Oncotarget, Vol. 6, No. 15, 01.01.2015, p. 13520-13538.

Research output: Contribution to journalArticle

Sánchez-Bailón, MP, Calcabrini, A, Mayoral-Varo, V, Molinari, A, Wagner, KU, Losada, JP, Ciordia, S, Albar, JP & Martín-Pérez, J 2015, 'Cyr61 as mediator of Src signaling in triple negative breast cancer cells', Oncotarget, vol. 6, no. 15, pp. 13520-13538. https://doi.org/10.18632/oncotarget.3760
Sánchez-Bailón MP, Calcabrini A, Mayoral-Varo V, Molinari A, Wagner KU, Losada JP et al. Cyr61 as mediator of Src signaling in triple negative breast cancer cells. Oncotarget. 2015 Jan 1;6(15):13520-13538. https://doi.org/10.18632/oncotarget.3760
Sánchez-Bailón, María Pilar ; Calcabrini, Annarica ; Mayoral-Varo, Víctor ; Molinari, Agnese ; Wagner, Kay Uwe ; Losada, Jesús Pérez ; Ciordia, Sergio ; Albar, Juan Pablo ; Martín-Pérez, Jorge. / Cyr61 as mediator of Src signaling in triple negative breast cancer cells. In: Oncotarget. 2015 ; Vol. 6, No. 15. pp. 13520-13538.
@article{0221f2c798db4995908d4fbeb92c53d5,
title = "Cyr61 as mediator of Src signaling in triple negative breast cancer cells",
abstract = "SFKs are involved in tumorigenesis and metastasis. Here we analyzed c-Src contribution to initial steps of metastasis by tetracycline-dependent expression of a specific shRNA-c-Src, which suppressed c-Src mRNA and protein levels in metastatic MDA-MB-231 cells. c-Src suppression did not alter cell proliferation or survival, but it significantly reduced anchorage-independent growth. Concomitantly with diminished tyrosine-phosphorylation/activation of Fak, caveolin-1, paxillin and p130CAS, c-Src depletion also inhibited cellular migration, invasion and transendothelial migration. Quantitative proteomic analyses of the secretome showed that Cyr61 levels, which were detected in the exosomal fraction, were diminished upon shRNA-c-Src expression. In contrast, Cyr61 expression was unaltered inside cells. Cyr61 partially colocalized with cis-Golgi gp74 marker and with exosomal marker CD63, but c-Src depletion did not alter their cellular distribution. In SUM159PT cells, transient c-Src suppression also reduced secreted exosomal Cyr61 levels. Furthermore, conditional expression of a c-Src dominant negative mutant (SrcDN, c-Src-K295M/Y527F) in MDA-MB-231 and in SUM159PT diminished secreted Cyr61 as well. Cyr61 transient suppression in MDA-MB-231 inhibited invasion and transendothelial migration. Finally, in both MDA-MB-231 and SUM159PT, a neutralizing Cyr61 antibody restrained migration. Collectively, these results suggest that c-Src regulates secreted proteins, including the exosomal Cyr61, which are involved in modulating the metastatic potential of triple negative breast cancer cells.",
keywords = "C-Src, Cyr61, Invasion, Migration, Triple negative breast cancer",
author = "S{\'a}nchez-Bail{\'o}n, {Mar{\'i}a Pilar} and Annarica Calcabrini and V{\'i}ctor Mayoral-Varo and Agnese Molinari and Wagner, {Kay Uwe} and Losada, {Jes{\'u}s P{\'e}rez} and Sergio Ciordia and Albar, {Juan Pablo} and Jorge Mart{\'i}n-P{\'e}rez",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.3760",
language = "English (US)",
volume = "6",
pages = "13520--13538",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "15",

}

TY - JOUR

T1 - Cyr61 as mediator of Src signaling in triple negative breast cancer cells

AU - Sánchez-Bailón, María Pilar

AU - Calcabrini, Annarica

AU - Mayoral-Varo, Víctor

AU - Molinari, Agnese

AU - Wagner, Kay Uwe

AU - Losada, Jesús Pérez

AU - Ciordia, Sergio

AU - Albar, Juan Pablo

AU - Martín-Pérez, Jorge

PY - 2015/1/1

Y1 - 2015/1/1

N2 - SFKs are involved in tumorigenesis and metastasis. Here we analyzed c-Src contribution to initial steps of metastasis by tetracycline-dependent expression of a specific shRNA-c-Src, which suppressed c-Src mRNA and protein levels in metastatic MDA-MB-231 cells. c-Src suppression did not alter cell proliferation or survival, but it significantly reduced anchorage-independent growth. Concomitantly with diminished tyrosine-phosphorylation/activation of Fak, caveolin-1, paxillin and p130CAS, c-Src depletion also inhibited cellular migration, invasion and transendothelial migration. Quantitative proteomic analyses of the secretome showed that Cyr61 levels, which were detected in the exosomal fraction, were diminished upon shRNA-c-Src expression. In contrast, Cyr61 expression was unaltered inside cells. Cyr61 partially colocalized with cis-Golgi gp74 marker and with exosomal marker CD63, but c-Src depletion did not alter their cellular distribution. In SUM159PT cells, transient c-Src suppression also reduced secreted exosomal Cyr61 levels. Furthermore, conditional expression of a c-Src dominant negative mutant (SrcDN, c-Src-K295M/Y527F) in MDA-MB-231 and in SUM159PT diminished secreted Cyr61 as well. Cyr61 transient suppression in MDA-MB-231 inhibited invasion and transendothelial migration. Finally, in both MDA-MB-231 and SUM159PT, a neutralizing Cyr61 antibody restrained migration. Collectively, these results suggest that c-Src regulates secreted proteins, including the exosomal Cyr61, which are involved in modulating the metastatic potential of triple negative breast cancer cells.

AB - SFKs are involved in tumorigenesis and metastasis. Here we analyzed c-Src contribution to initial steps of metastasis by tetracycline-dependent expression of a specific shRNA-c-Src, which suppressed c-Src mRNA and protein levels in metastatic MDA-MB-231 cells. c-Src suppression did not alter cell proliferation or survival, but it significantly reduced anchorage-independent growth. Concomitantly with diminished tyrosine-phosphorylation/activation of Fak, caveolin-1, paxillin and p130CAS, c-Src depletion also inhibited cellular migration, invasion and transendothelial migration. Quantitative proteomic analyses of the secretome showed that Cyr61 levels, which were detected in the exosomal fraction, were diminished upon shRNA-c-Src expression. In contrast, Cyr61 expression was unaltered inside cells. Cyr61 partially colocalized with cis-Golgi gp74 marker and with exosomal marker CD63, but c-Src depletion did not alter their cellular distribution. In SUM159PT cells, transient c-Src suppression also reduced secreted exosomal Cyr61 levels. Furthermore, conditional expression of a c-Src dominant negative mutant (SrcDN, c-Src-K295M/Y527F) in MDA-MB-231 and in SUM159PT diminished secreted Cyr61 as well. Cyr61 transient suppression in MDA-MB-231 inhibited invasion and transendothelial migration. Finally, in both MDA-MB-231 and SUM159PT, a neutralizing Cyr61 antibody restrained migration. Collectively, these results suggest that c-Src regulates secreted proteins, including the exosomal Cyr61, which are involved in modulating the metastatic potential of triple negative breast cancer cells.

KW - C-Src

KW - Cyr61

KW - Invasion

KW - Migration

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84931035386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931035386&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.3760

DO - 10.18632/oncotarget.3760

M3 - Article

VL - 6

SP - 13520

EP - 13538

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 15

ER -